IDHIFA (enasidenib mesylate)
ANTINEOPLASTIC - ISOCITRATE DEHYDROGENASE-2 INHIBITOR (IDH2) · ACUTE MYELOID LEUKEMIA WITH ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
CELGENE/BMS
Drug class
Antineoplastic - Isocitrate Dehydrogenase-2 Inhibitor (IDH2)
The therapeutic drug class "Antineoplastic - Isocitrate Dehydrogenase-2 Inhibitor (IDH2)" comprises targeted oncology agents that selectively inhibit mutated forms of the mitochondrial enzyme isocitrate dehydrogenase-2. Read more about Antineoplastic - Isocitrate Dehydrogenase-2 Inhibitor (IDH2)
2 drugs in this class 2 manufacturers
Drugs in Antineoplastic - Isocitrate Dehydrogenase-2 Inhibitor (IDH2)
VORANIGO (vorasidenib citrate)
ANTINEOPLASTIC - ISOCITRATE DEHYDROGENASE-2 INHIBITOR (IDH2) · DIFFUSE ASTROCYTOMA ·+1
SERVIER PHARMAC
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Isocitrate Dehydrogenase-2 Inhibitor (IDH2) preselected. Add indication or manufacturer filters there.
The therapeutic drug class "Antineoplastic - Isocitrate Dehydrogenase-2 Inhibitor (IDH2)" comprises targeted oncology agents that selectively inhibit mutated forms of the mitochondrial enzyme isocitrate dehydrogenase-2.
By blocking the aberrant enzymatic conversion of alpha-ketoglutarate to the oncometabolite 2-hydroxyglutarate, these therapies reduce intracellular 2-hydroxyglutarate concentrations, reverse epigenetic hypermethylation, and induce cellular differentiation of malignant blast cells.
Agents in this class, such as enasidenib, are primarily indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring a confirmed IDH2 mutation.
-
fda.gov
The therapeutic drug class "Antineoplastic - Isocitrate Dehydrogenase-2 Inhibitor (IDH2)" comprises targeted oncology agents that selectively inhibit mutated forms of the mitochondrial enzyme isocitrate dehydrogenase-2 Agents in this class, such as enasidenib, are primarily indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring a confirmed IDH2 mutation
-
nih.gov
The therapeutic drug class "Antineoplastic - Isocitrate Dehydrogenase-2 Inhibitor (IDH2)" comprises targeted oncology agents that selectively inhibit mutated forms of the mitochondrial enzyme isocitrate dehydrogenase-2 By blocking the aberrant enzymatic conversion of alpha-ketoglutarate to the oncometabolite 2-hydroxyglutarate, these therapies reduce intracellular 2-hydroxyglutarate concentrations, reverse epigenetic hypermethylation, and induce cellular differentiation of malignant blast cells ...
-
nih.gov
By blocking the aberrant enzymatic conversion of alpha-ketoglutarate to the oncometabolite 2-hydroxyglutarate, these therapies reduce intracellular 2-hydroxyglutarate concentrations, reverse epigenetic hypermethylation, and induce cellular differentiation of malignant blast cells
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.